In vitro and in vivo trypanocidal activity of H2bdtc-loaded solid lipid nanoparticles

摘要: The parasite Trypanosoma cruzi causes Chagas disease, which remains a serious public health concern and continues to victimize thousands of people, primarily in the poorest regions Latin America. In search for new therapeutic drugs against T. cruzi, here we have evaluated both vitro vivo activity 5-hydroxy-3-methyl-5-phenyl-pyrazoline-1-(S-benzyl dithiocarbazate) (H2bdtc) as free compound or encapsulated into solid lipid nanoparticles (SLN); compared results with those achieved by using currently employed drug, benznidazole. H2bdtc (a) effectively reduced parasitemia mice at concentrations 100 times lower than that normally benznidazole (clinically applied concentration 400 µmol kg−1 day−1); (b) diminished inflammation lesions liver heart; (c) resulted 100% survival infected cruzi. Therefore, is potent trypanocidal agent.